GE HealthCare and Mayo Clinic launch theranostics study to personalize prostate cancer treatment
GE HealthCare and Mayo Clinic have launched the MI-BET research collaboration, a theranostics study aimed at developing a more personalized approach to radioligand therapy (RLT) for advanced prostate cancer patients. The study builds on their 2023 Strategic Radiology Research Alliance and focuses on using molecular imaging biomarkers to determine when to end therapy, potentially improving treatment outcomes and reducing unnecessary side effects.
Key quotes
GE HealthCare and Mayo Clinic today announced the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) research collaboration, a novel theranostics study designed to explore a more personalized approach to radioligand therapy (RLT) for patients with advanced prostate cancer.
This collaboration is a direct result of the 2023 Strategic Radiology Research Alliance between Mayo Clinic and GE HealthCare, aimed at transforming the experience of patients and clinicians in the practice of radiology and the delivery of novel therapies.
From the article
CHICAGO, Ill. and ROCHESTER, Minn. — GE HealthCare and Mayo Clinic today announced the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) research collaboration, a novel theranostics study designed to explore a more personalized approach to r
Continue reading on mayocl.inYou might also wanna read
A Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer
clinicaltrials.gov·1d ago
GE HealthCare Unveils AI and Radiopharmaceutical Innovations to Expand Nuclear Medicine Access at SNMMI 2026
GE HealthCare is showcasing new AI-enabled workflows, radiopharmaceuticals, and imaging innovations at the 2026 SNMMI Annual Meeting to help
stocktitan.net·1mo agoLarge, long-term study shows dutasteride reduced prostate cancer risk in men at increased risk of the disease
GSK·17y ago
Modelling Study Projects Rapid Growth in Radioligand Therapy Patient Populations Across EU and UK Healthcare Systems
This modelling study estimates the future patient populations eligible for radioligand therapies (RLTs) across EU-27 member states and the U
thelancet.com·1mo ago
Development and Validation of a Non-Invasive AI Diagnostic Model for Prostate Cancer Using Multiparametric MRI and PSMA PET/CT
clinicaltrials.gov·1d ago
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
doi.org·6d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.